• Human metapneumovirus spiked this spring as cases of COVID and RSV fell.

• According to the CDC, 19.6% of antigen tests and nearly 11% of PCR tests for HMPV, were positive in the US in early March.

• Symptoms of HMPV include cough, fever, nasal congestion, and shortness of breath.

Cases of another type of respiratory virus have spiked this spring, just as COVID-19 and RSV rates were finally falling in the US.

According to the CDC, 19.6% of antigen tests and nearly 11% of PCR tests for human metapneumovirus, or HMPV, were positive in the US in early March.

The nearly 11% of positive PCR cases is up 36% since before the COVID-19 pandemic when PCR tests for HMPV were coming back with a rate of 7% positivity, according to the CDC.

In contrast, COVID-19 cases were down nearly 30% at the beginning of March, according to the World Health Organization, and the number of people being hospitalized for RSV was down to 1.2 people per 100,000 in March from 4.5 people per 100,000 in January, according to the CDC.

Symptoms of HMPV include cough, fever, nasal congestion, and shortness of breath, according to the CDC. The symptoms could progress into bronchitis, pneumonia, or other similar viruses that cause upper and lower respiratory infections.

The CDC said some might be sicker for longer than others, and the duration of the virus depends on the severity, but for the most part, is similar in length to other respiratory infections caused by viruses.

The virus is spread by coughs and sneezes, close personal contact, and touching surfaces infected with the virus, then touching the mouth, nose, or eyes.

According to CNN, there’s no vaccine for HMPV, nor is there an antiviral drug to treat it.

Read the original article on Insider

Adblock test (Why?)

Source link

• Human metapneumovirus spiked this spring as cases of COVID and RSV fell.
• According to the CDC, 19.6% of antigen tests and nearly 11% of PCR tests for HMPV, were positive in the US in early March.
• Symptoms of HMPV include cough, fever, nasal congestion, and shortness of breath.

Cases of another type of respiratory virus have spiked this spring, just as COVID-19 and RSV rates were finally falling in the US.

According to the CDC, 19.6% of antigen tests and nearly 11% of PCR tests for human metapneumovirus, or HMPV, were positive in the US in early March.

The nearly 11% of positive PCR cases is up 36% since before the COVID-19 pandemic when PCR tests for HMPV were coming back with a rate of 7% positivity, according to the CDC.

In contrast, COVID-19 cases were down nearly 30% at the beginning of March, according to the World Health Organization, and the number of people being hospitalized for RSV was down to 1.2 people per 100,000 in March from 4.5 people per 100,000 in January, according to the CDC.

Symptoms of HMPV include cough, fever, nasal congestion, and shortness of breath, according to the CDC. The symptoms could progress into bronchitis, pneumonia, or other similar viruses that cause upper and lower respiratory infections.

The CDC said some might be sicker for longer than others, and the duration of the virus depends on the severity, but for the most part, is similar in length to other respiratory infections caused by viruses.

The virus is spread by coughs and sneezes, close personal contact, and touching surfaces infected with the virus, then touching the mouth, nose, or eyes.

According to CNN, there’s no vaccine for HMPV, nor is there an antiviral drug to treat it.

Read the original article on Insider

Source link

By Halyna Mihalik

Saskatoon virologist Alyson Kelvin, who studies infectious diseases, has been awarded half a million dollars from the Canadian government to research the rapidly growing disease of mpox, formerly known as monkeypox.

The same amount was also awarded to one of Kelvin’s colleagues for related studies, for a combined total of $1 million. The government put out a funding call for research to better understand the virus last September, and issued another funding call in December.

“Last year, the increase of mpox cases globally led to a public health emergency of international concern,” said Kelvin.

Kelvin said she and her team of scientists from the University of Manitoba and UCLA will be researching the rapidly growing virus, specifically analyzing the situation in the Democratic Republic of the Congo, where mpox is most prominent.

Although Kelvin said she won’t be visiting the African country herself, other members of her team will be working on the ground, and the UCLA has a research base there.

Mpox originated in the DRC in the 1970s, and since the early 2000s the country has seen nearly 2,000 cases of mpox a year.

By examining how people in the area interact with animals that carry the virus, Kelvin said her team will try to limit the crossover of mpox from animals to humans.

“When human cases are reported of mpox, we will then go look at that area for animals that could be infected and figure out if these people had contact with wild animals,” said Kelvin.

More than 1,000 mpox cases were found in the North American beaver in Canada last year, and Kelvin said she will be investigating how animals such as beavers and prairie dogs could be infected by the virus.

Her research will also try to identify if domestic animals, such as dogs, could also contract mpox. If people who have contracted mpox from a wild animal could pass the virus onto their pet, she said it would ultimately lead to more cases.

Kelvin said the Canadian government stepping in to help examine an issue present in Africa is important and necessary.

“What happens in one place will also affect us,” she said. “Problems that occur in other countries are still our problem as well.”

Adblock test (Why?)

Source link